New England Journal of Medicine · 1977 · 291 citations · 34 references
Tumor BiologyEndocrine OncologyPancreatic IsletsPancreatic CancerDiabetesImmunologyHistopathologyPathologyGastroenterologySomatostatin ContentEnteric Hormone ProfileSomatostatin-containing TumorPancreas TransplantationEndocrinologyMedicineCancer Research
We studied the pancreatic and enteric hormone profile of a 46-year-old woman who had hyperglycemia and a pancreatic tumor. Before operation, there was no evidence of overproduction of glucagon or insulin. The tumor's ultrastructure had a distinctive endocrine morphology, resembling D cells. Prompted by the recent demonstration of somatostatin in D cells of pancreatic islets, we analyzed the tumor and found a large quantity of immunoreactive somatostatin (301 ng per milligram of tissue). Insulin, glucagon, gastrin, vasoactive intestinal polypeptide and human pancreatic polypeptide were present in only trace quantities. The tumor cells were cultured in monolayers, which remained viable up to 51 days and released somatostatin into the culture medium. In seven insulinomas and two glucagonomas, we found the somatostatin content either much lower (less than 0.6 ng per milligram of tissue) or undetectable. After complete resection of the tumor, our patient became euglycemic and has remained so for the past 20 months.
34
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Paul Brazeau, Wylie Vale, Roger Burgus et al. · Science · 1973 · 3.5K citations